12KZ

Crystal structure of human KRAS G12C covalently bound to thiazol-2-yl piperidine compound 3

This is a non-PDB format compatible entry.

Summary for 12KZ

• Entry DOI: 10.2210/pdb12kz/pdb
• Descriptor: Isoform 2B of GTPase KRas, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ... (6 entities in total)
• Functional Keywords: inhibitor, gtpase, signaling protein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 22163.08

Authors

Mohr, C. (deposition date: 2026-04-10, release date: 2026-08-12, Last modification date: 2026-08-26)

Primary citation

Rast, S.,Morgan-Fisher, M.,Blomquist, S.D.,Cadahia, J.P.,Cowland, S.,Franch, T.,Glibstrup, E.,Gouliaev, A.,Haahr Hansen, M.,Kontijevskis, A.,Kronborg, T.,Moretti, L.,Nadali, A.,Nielsen, S.,Leth-Petersen, S.,Rabe, M.,Alafate, A.,Allen, J.R.,Banerjee, A.,Booker, S.K.,Butler, J.R.,Hot, I.,Huang, D.,Kaller, M.R.,Kapoor, R.,Liu, Q.,Lopez, P.,Ma, V.,Manoni, F.,Medina, J.M.,Pickrell, A.J.,Wang, H.L.,Xie, J.,Zhang, W.,Mohr, C.,Chen, K.,Saiki, A.Y.,Wang, P.,Leavitt, M.,Rex, K.,Zhong, G.,Zou, L.,Lade, J.,Dahal, U.P.,Farhan, N.,Agarwal, P.,Zandkarimi, B.,Zhu, K.,Husemoen, G.,Tamayo, N.A.,Lanman, B.A.
Property-Biased Covalent DNA-Encoded Library Screening Enabled the Discovery of AM-8719, A Structurally Novel, CNS-Penetrant KRAS G12C Inhibitor.
J.Med.Chem., 69:19050-19064, 2026

PubMed Abstract: Activating mutations in the Kirsten rat sarcoma (KRAS) gene are prevalent oncogenic drivers in nonsmall cell lung cancer (NSCLC). Patients harboring KRAS-mutant lung cancers frequently develop central nervous system (CNS) metastases. Although approved KRAS G12C inhibitors (i.e., sotorasib and adagrasib) show promising clinical CNS activity, these agents demonstrate low preclinical brain-to-plasma ratios, raising the question of whether compounds with elevated preclinical Kp,uu,brain values might show enhanced clinical performance. Here, we report the first successful application of DNA-encoded library (DEL) screening technology to the identification of CNS-penetrant covalent inhibitors of KRAS G12C. In this effort, a property-biased covalent DEL-screening approach enabled the discovery of a structurally novel series of hydrogen bond donor-free KRAS G12C inhibitors with improved CNS exposure. Leveraging structure-based design, we refined this hit series to deliver lead compound AM-8719, a CNS-penetrant, orally efficacious KRAS G12C inhibitor exhibiting 200-fold improved potency with respect to initial screening hits.

PubMed: 42593915
DOI: 10.1021/acs.jmedchem.6c01357

Experimental method

X-RAY DIFFRACTION (1.45 Å)